Clinical Nuclear Medicine

Skip Navigation LinksHome > April 2013 - Volume 38 - Issue 4 > Radioiodine Therapy for Graves Disease: Thyroid Absorbed Dos...
Text sizing:
Clinical Nuclear Medicine:
doi: 10.1097/RLU.0b013e3182816717
Original Articles

Radioiodine Therapy for Graves Disease: Thyroid Absorbed Dose of 300 Gy—Tuning the Target for Therapy Planning

Willegaignon, José PhD; Sapienza, Marcelo Tatit PhD; Buchpiguel, Carlos Alberto PhD

Collapse Box


Purposes: Based on the committed thyroid absorbed dose, the aim was to compare the efficiency of 131I therapy against Graves disease (GD) within 1 year after treatment and, by exploring the dose-response relationship, indicate an absorbed dose to be targeted into patient therapeutic planning.

Methods: Thyroid-absorbed doses were calculated to 196 patients with GD by applying Medical Internal Radiation Dose formalism and taking into account administered 131I activity, thyroid radioiodine uptake, effective half-life, and gland tissue mass. Statistical analysis was applied to assess the relationship between absorbed doses and the patient’s clinical response.

Results: Overall, successful therapy was achieved in 167 patients, whereas in 29 the disease persisted, even though 64.8% and 89.3% of all the treated patients had received, respectively, thyroid absorbed dose and activity superior to 300 Gy and 11.1 MBq/g (300 μCi/g) of thyroid tissue. Among those in whom the disease persisted, 24 (83%) had a 6- to 24-hour 131I uptake ratio equal or superior to 0.9, whereas only 5 (17%) presented a lower ratio. According to statistical analysis, there was no difference in cure rate between the groups that received 300 Gy or less and that which received more (84.1% vs 85.8%, P = 0.8336).

Conclusions: A thyroid absorbed dose of 300 Gy is plausible as a targeted therapeutic dose in GD therapy planning, because statistical analysis has proven there to be no advantage in treating patients with doses above this level. On the other hand, numerous efforts should be made to develop an optimized and easily applicable protocol of patient-specific dosimetry and to provide data that show its clinical impact on patient management.

© 2013 by Lippincott Williams & Wilkins


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.